Senti Biosciences (NASDAQ:SNTI) Releases Earnings Results, Misses Expectations By $0.08 EPS

Senti Biosciences (NASDAQ:SNTI – Get Free Report) released its earnings results on Friday. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.08), FiscalAI reports. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.01 million.

Senti Biosciences Stock Performance

NASDAQ SNTI opened at $0.45 on Friday. The stock’s fifty day moving average is $0.73 and its two-hundred day moving average is $0.87. The firm has a market capitalization of $13.99 million, a P/E ratio of -0.23 and a beta of 2.10. Senti Biosciences has a fifty-two week low of $0.33 and a fifty-two week high of $2.88.

Get Senti Biosciences alerts:

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of SNTI. Armistice Capital LLC acquired a new position in shares of Senti Biosciences during the 2nd quarter valued at about $1,883,000. Geode Capital Management LLC increased its position in Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after purchasing an additional 117,588 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Senti Biosciences during the third quarter worth about $117,000. Virtu Financial LLC acquired a new stake in Senti Biosciences during the fourth quarter worth about $46,000. Finally, Jane Street Group LLC purchased a new position in Senti Biosciences during the fourth quarter worth about $40,000. Hedge funds and other institutional investors own 25.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on SNTI shares. Chardan Capital boosted their price target on shares of Senti Biosciences from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Senti Biosciences in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Check Out Our Latest Report on Senti Biosciences

About Senti Biosciences

(Get Free Report)

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.

Featured Stories

• Five stocks we like better than Senti Biosciences
• MarketBeat Week in Review – 08/10 – 08/14
• Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
• Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
• NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270

Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.